Resources

ELRIG announced the keynote speakers for Cell and Gene Therapy 2026 - Drs Stephen Ward (Cell and Gene Therapy Catapult) and Annarita Miccio (Imagine Institute).

The British Business Bank has made a £50 million cornerstone commitment to Epidarex Capital’s next fund.

Brainomix has been selected by Boehringer Ingelheim, the leading biopharmaceutical company providing therapeutic options for interstitial lung disease (ILD).

Coulter Partners successfully completed a search assignment for mOm Incubators and to place Daniel Green as Chief Operating Officer.

We’re excited to launch She Steers, NEDs in Biotech, a specialist Non-Executive Director (NED) board programme created for women across life sciences and biotech.

J.P. Morgan’s healthcare conference may be wrapped up, but it has set some tangible momentum and without doubt a more buoyant mood for global life sciences going into 2026.

PIR International recently partnered with Slingshot Therapeutics in appointing Bobby Soni as Chief Business Officer.

AAVantgarde Bio, a clinical-stage biotechnology company pioneering therapies for inherited retinal diseases (IRDs), has announced the completion of enrollment in LUCE-1.

An acknowledgment from Astrea Bioseparations celebrating LIB Therapeutics' achievement of FDA approval for LEROCHOL™, including some collaboration efforts.

In this blog, Linda Bedenik, Senior Policy and Public Affairs Manager at BIA, explores Biosolutions, defining what they are and their potential to solve global challenges beyond health.

As we settle into the rhythms of daily life and gather our thoughts about the year ahead, our policy experts have weighed in on what the life sciences sector might expect in 2026.

Coulter Partners successfully led a search assignment for Trevi Therapeutics, placing David Hastings as Chief Financial Officer (CFO).

OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced the closure of its £2.5 million seed funding round.

This week JPM kicks off in San Francisco with BIA hosting a UK Reception. A significant week for BIA too with the long-awaited announcement of our new CEO.

We are delighted to announce the appointment of Professor Chris Molloy as our new Chief Executive Officer, starting in May 2026.

Amici Procurement Solutions Rebrands as MyAmici. The rebrand reflects the organization’s strategic evolution from a procurement-focused provider to a comprehensive, end-to-end LabOps platform supporting biotech, medtech, and life-science organisations across every stage of growth.

Complement Therapeutics is one of the leading new gene therapy companies entering into clinical trials. Based on research from the University of Manchester, the company's lead candidate CTx001 is a novel adeno-associated virus (AAV)-based gene therapy targeting an advanced form of dry AMD that leads to irreversible vision loss, with limited therapeutic options. With strong funding and an experienced management team, Complement has made rapid progress and this Fast Track designation comes after IND clearance in December.

Pioneer Group, a specialist in life science infrastructure and venture building, and global biopharmaceutical company AbbVie, have crowned Alceus Bio the winner of their 2025 Golden Ticket programme.

NRG Therapeutics Ltd has announced that the first participants have been dosed in its first-in-human Phase 1 clinical trial of its lead candidate NRG5051 being developed as a treatment for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) and Parkinson’s.